RCG Orange Dc is a medicare approved dialysis facility center in Orange, New Jersey and it has 20 dialysis stations. It is located in Essex county at 151 Central Ave, Orange, NJ, 07050. You can reach out to the office of RCG Orange Dc at (973) 675-3400. This dialysis clinic is managed and/or owned by Fresenius Medical Care. RCG Orange Dc has the following ownership type - Profit. It was first certified by medicare in February, 2000. The medicare id for this facility is 312533 and it accepts patients under medicare ESRD program.
| Name | RCG Orange Dc |
|---|---|
| Location | 151 Central Ave, Orange, New Jersey |
| No. of Dialysis Stations | 20 |
| Medicare ID | 312533 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Profit |
| Late Shifts | Yes |
| 151 Central Ave, Orange, New Jersey, 07050 | |
| (973) 675-3400 | |
News Archive
Janssen Research & Development, LLC (Janssen) today announced it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for simeprevir, an NS3/4A protease inhibitor marketed as OLYSIO™ in the United States, in combination with the nucleotide analog NS5B polymerase inhibitor sofosbuvir developed by Gilead Sciences, Inc.
Guardian health editor Sarah Boseley examines why children have been excluded from WHO targets on non-communicable diseases (NCDs) in this post in her "Global Health Blog," writing, "Children die from cancer, heart disease and other NCDs but they are in danger of being forgotten as global targets for action are drawn up, say health groups."
The Ontario Long Term Care Association (OLTCA) is pleased to announce the opening of Together We Care Convention and Trade Show, jointly organized by OLTCA and the Ontario Retirement Communities Association (ORCA). The convention will take place on Sunday, April 25th until Tuesday, April 27th at the Metro Toronto Convention Centre on the lower level.
The international First-line Radiosurgery for Small-Cell Lung Cancer (FIRE-SCLC) analysis led by University of Colorado Cancer Center researchers and published today in JAMA Oncology details clinical outcomes for 710 patients with brain metastases from small cell lung cancer treated with first-line stereotactic radiosurgery (SRS), without prior treatment with whole-brain radiation (WBRT) or prophylactic cranial irradiation (PCI).
NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, today announced that the Company will be presenting its Autologous Adult Stem Cell VSEL Technology for the Treatment of Battlefield Wounds at The USU-HJF Military Medicine Symposium in Washington DC, September 23rd, 2010.
› Verified 9 days ago
| NPI Number | 1588768352 |
| Organization Name | Renex Dialysis Clinic Of Orange Inc |
| Doing Business As | Renex Dialysis Clinic Of Orange Inc |
| Address | 151 Central Avenue Orange, New Jersey, 07050 |
| Phone Number | (973) 675-3400 |
News Archive
Janssen Research & Development, LLC (Janssen) today announced it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for simeprevir, an NS3/4A protease inhibitor marketed as OLYSIO™ in the United States, in combination with the nucleotide analog NS5B polymerase inhibitor sofosbuvir developed by Gilead Sciences, Inc.
Guardian health editor Sarah Boseley examines why children have been excluded from WHO targets on non-communicable diseases (NCDs) in this post in her "Global Health Blog," writing, "Children die from cancer, heart disease and other NCDs but they are in danger of being forgotten as global targets for action are drawn up, say health groups."
The Ontario Long Term Care Association (OLTCA) is pleased to announce the opening of Together We Care Convention and Trade Show, jointly organized by OLTCA and the Ontario Retirement Communities Association (ORCA). The convention will take place on Sunday, April 25th until Tuesday, April 27th at the Metro Toronto Convention Centre on the lower level.
The international First-line Radiosurgery for Small-Cell Lung Cancer (FIRE-SCLC) analysis led by University of Colorado Cancer Center researchers and published today in JAMA Oncology details clinical outcomes for 710 patients with brain metastases from small cell lung cancer treated with first-line stereotactic radiosurgery (SRS), without prior treatment with whole-brain radiation (WBRT) or prophylactic cranial irradiation (PCI).
NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, today announced that the Company will be presenting its Autologous Adult Stem Cell VSEL Technology for the Treatment of Battlefield Wounds at The USU-HJF Military Medicine Symposium in Washington DC, September 23rd, 2010.
› Verified 9 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that nephrologists always communicated and cared for them. | 65% | 67% |
| Patients who reported that nephrologists usually communicated and cared for them. | 12% | 15% |
| Patients who reported that nephrologists sometimes or never communicated and cared for them. | 23% | 18% |
| Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 50% | 60% |
| Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 39% | 26% |
| Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 11% | 14% |
News Archive
Janssen Research & Development, LLC (Janssen) today announced it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for simeprevir, an NS3/4A protease inhibitor marketed as OLYSIO™ in the United States, in combination with the nucleotide analog NS5B polymerase inhibitor sofosbuvir developed by Gilead Sciences, Inc.
Guardian health editor Sarah Boseley examines why children have been excluded from WHO targets on non-communicable diseases (NCDs) in this post in her "Global Health Blog," writing, "Children die from cancer, heart disease and other NCDs but they are in danger of being forgotten as global targets for action are drawn up, say health groups."
The Ontario Long Term Care Association (OLTCA) is pleased to announce the opening of Together We Care Convention and Trade Show, jointly organized by OLTCA and the Ontario Retirement Communities Association (ORCA). The convention will take place on Sunday, April 25th until Tuesday, April 27th at the Metro Toronto Convention Centre on the lower level.
The international First-line Radiosurgery for Small-Cell Lung Cancer (FIRE-SCLC) analysis led by University of Colorado Cancer Center researchers and published today in JAMA Oncology details clinical outcomes for 710 patients with brain metastases from small cell lung cancer treated with first-line stereotactic radiosurgery (SRS), without prior treatment with whole-brain radiation (WBRT) or prophylactic cranial irradiation (PCI).
NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, today announced that the Company will be presenting its Autologous Adult Stem Cell VSEL Technology for the Treatment of Battlefield Wounds at The USU-HJF Military Medicine Symposium in Washington DC, September 23rd, 2010.
› Verified 9 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 60% | 62% |
| Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 20% | 20% |
| Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 20% | 18% |
| Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 56% | 62% |
| Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 29% | 26% |
| Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 15% | 12% |
News Archive
Janssen Research & Development, LLC (Janssen) today announced it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for simeprevir, an NS3/4A protease inhibitor marketed as OLYSIO™ in the United States, in combination with the nucleotide analog NS5B polymerase inhibitor sofosbuvir developed by Gilead Sciences, Inc.
Guardian health editor Sarah Boseley examines why children have been excluded from WHO targets on non-communicable diseases (NCDs) in this post in her "Global Health Blog," writing, "Children die from cancer, heart disease and other NCDs but they are in danger of being forgotten as global targets for action are drawn up, say health groups."
The Ontario Long Term Care Association (OLTCA) is pleased to announce the opening of Together We Care Convention and Trade Show, jointly organized by OLTCA and the Ontario Retirement Communities Association (ORCA). The convention will take place on Sunday, April 25th until Tuesday, April 27th at the Metro Toronto Convention Centre on the lower level.
The international First-line Radiosurgery for Small-Cell Lung Cancer (FIRE-SCLC) analysis led by University of Colorado Cancer Center researchers and published today in JAMA Oncology details clinical outcomes for 710 patients with brain metastases from small cell lung cancer treated with first-line stereotactic radiosurgery (SRS), without prior treatment with whole-brain radiation (WBRT) or prophylactic cranial irradiation (PCI).
NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, today announced that the Company will be presenting its Autologous Adult Stem Cell VSEL Technology for the Treatment of Battlefield Wounds at The USU-HJF Military Medicine Symposium in Washington DC, September 23rd, 2010.
› Verified 9 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 79% | 80% |
| Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 21% | 20% |
| Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 62% | 68% |
| Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 25% | 20% |
| Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 13% | 12% |
News Archive
Janssen Research & Development, LLC (Janssen) today announced it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for simeprevir, an NS3/4A protease inhibitor marketed as OLYSIO™ in the United States, in combination with the nucleotide analog NS5B polymerase inhibitor sofosbuvir developed by Gilead Sciences, Inc.
Guardian health editor Sarah Boseley examines why children have been excluded from WHO targets on non-communicable diseases (NCDs) in this post in her "Global Health Blog," writing, "Children die from cancer, heart disease and other NCDs but they are in danger of being forgotten as global targets for action are drawn up, say health groups."
The Ontario Long Term Care Association (OLTCA) is pleased to announce the opening of Together We Care Convention and Trade Show, jointly organized by OLTCA and the Ontario Retirement Communities Association (ORCA). The convention will take place on Sunday, April 25th until Tuesday, April 27th at the Metro Toronto Convention Centre on the lower level.
The international First-line Radiosurgery for Small-Cell Lung Cancer (FIRE-SCLC) analysis led by University of Colorado Cancer Center researchers and published today in JAMA Oncology details clinical outcomes for 710 patients with brain metastases from small cell lung cancer treated with first-line stereotactic radiosurgery (SRS), without prior treatment with whole-brain radiation (WBRT) or prophylactic cranial irradiation (PCI).
NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, today announced that the Company will be presenting its Autologous Adult Stem Cell VSEL Technology for the Treatment of Battlefield Wounds at The USU-HJF Military Medicine Symposium in Washington DC, September 23rd, 2010.
› Verified 9 days ago
| Dialysis patients with Hemoglobin data | 71 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 14 |
News Archive
Janssen Research & Development, LLC (Janssen) today announced it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for simeprevir, an NS3/4A protease inhibitor marketed as OLYSIO™ in the United States, in combination with the nucleotide analog NS5B polymerase inhibitor sofosbuvir developed by Gilead Sciences, Inc.
Guardian health editor Sarah Boseley examines why children have been excluded from WHO targets on non-communicable diseases (NCDs) in this post in her "Global Health Blog," writing, "Children die from cancer, heart disease and other NCDs but they are in danger of being forgotten as global targets for action are drawn up, say health groups."
The Ontario Long Term Care Association (OLTCA) is pleased to announce the opening of Together We Care Convention and Trade Show, jointly organized by OLTCA and the Ontario Retirement Communities Association (ORCA). The convention will take place on Sunday, April 25th until Tuesday, April 27th at the Metro Toronto Convention Centre on the lower level.
The international First-line Radiosurgery for Small-Cell Lung Cancer (FIRE-SCLC) analysis led by University of Colorado Cancer Center researchers and published today in JAMA Oncology details clinical outcomes for 710 patients with brain metastases from small cell lung cancer treated with first-line stereotactic radiosurgery (SRS), without prior treatment with whole-brain radiation (WBRT) or prophylactic cranial irradiation (PCI).
NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, today announced that the Company will be presenting its Autologous Adult Stem Cell VSEL Technology for the Treatment of Battlefield Wounds at The USU-HJF Military Medicine Symposium in Washington DC, September 23rd, 2010.
› Verified 9 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 131 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 1220 |
| Percentage of adult patients getting regular hemodialysis at the center | 98 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Janssen Research & Development, LLC (Janssen) today announced it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for simeprevir, an NS3/4A protease inhibitor marketed as OLYSIO™ in the United States, in combination with the nucleotide analog NS5B polymerase inhibitor sofosbuvir developed by Gilead Sciences, Inc.
Guardian health editor Sarah Boseley examines why children have been excluded from WHO targets on non-communicable diseases (NCDs) in this post in her "Global Health Blog," writing, "Children die from cancer, heart disease and other NCDs but they are in danger of being forgotten as global targets for action are drawn up, say health groups."
The Ontario Long Term Care Association (OLTCA) is pleased to announce the opening of Together We Care Convention and Trade Show, jointly organized by OLTCA and the Ontario Retirement Communities Association (ORCA). The convention will take place on Sunday, April 25th until Tuesday, April 27th at the Metro Toronto Convention Centre on the lower level.
The international First-line Radiosurgery for Small-Cell Lung Cancer (FIRE-SCLC) analysis led by University of Colorado Cancer Center researchers and published today in JAMA Oncology details clinical outcomes for 710 patients with brain metastases from small cell lung cancer treated with first-line stereotactic radiosurgery (SRS), without prior treatment with whole-brain radiation (WBRT) or prophylactic cranial irradiation (PCI).
NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, today announced that the Company will be presenting its Autologous Adult Stem Cell VSEL Technology for the Treatment of Battlefield Wounds at The USU-HJF Military Medicine Symposium in Washington DC, September 23rd, 2010.
› Verified 9 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at RCG Orange Dc with elevated calcium levels.
| Patients with hypercalcemia | 135 |
| Hypercalcemia patient months | 1254 |
| Patients with Serumphosphor | 140 |
| Patients with Serumphosphor less than 3.5 mg/dL | 20 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 31 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 27 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 18 |
| Patients with Serumphosphor greater than 7 mg/dL | 4 |
News Archive
Janssen Research & Development, LLC (Janssen) today announced it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for simeprevir, an NS3/4A protease inhibitor marketed as OLYSIO™ in the United States, in combination with the nucleotide analog NS5B polymerase inhibitor sofosbuvir developed by Gilead Sciences, Inc.
Guardian health editor Sarah Boseley examines why children have been excluded from WHO targets on non-communicable diseases (NCDs) in this post in her "Global Health Blog," writing, "Children die from cancer, heart disease and other NCDs but they are in danger of being forgotten as global targets for action are drawn up, say health groups."
The Ontario Long Term Care Association (OLTCA) is pleased to announce the opening of Together We Care Convention and Trade Show, jointly organized by OLTCA and the Ontario Retirement Communities Association (ORCA). The convention will take place on Sunday, April 25th until Tuesday, April 27th at the Metro Toronto Convention Centre on the lower level.
The international First-line Radiosurgery for Small-Cell Lung Cancer (FIRE-SCLC) analysis led by University of Colorado Cancer Center researchers and published today in JAMA Oncology details clinical outcomes for 710 patients with brain metastases from small cell lung cancer treated with first-line stereotactic radiosurgery (SRS), without prior treatment with whole-brain radiation (WBRT) or prophylactic cranial irradiation (PCI).
NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, today announced that the Company will be presenting its Autologous Adult Stem Cell VSEL Technology for the Treatment of Battlefield Wounds at The USU-HJF Military Medicine Symposium in Washington DC, September 23rd, 2010.
› Verified 9 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 114 |
| Patient months included in arterial venous fistula and catheter summaries | 935 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 65 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 16 |
News Archive
Janssen Research & Development, LLC (Janssen) today announced it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for simeprevir, an NS3/4A protease inhibitor marketed as OLYSIO™ in the United States, in combination with the nucleotide analog NS5B polymerase inhibitor sofosbuvir developed by Gilead Sciences, Inc.
Guardian health editor Sarah Boseley examines why children have been excluded from WHO targets on non-communicable diseases (NCDs) in this post in her "Global Health Blog," writing, "Children die from cancer, heart disease and other NCDs but they are in danger of being forgotten as global targets for action are drawn up, say health groups."
The Ontario Long Term Care Association (OLTCA) is pleased to announce the opening of Together We Care Convention and Trade Show, jointly organized by OLTCA and the Ontario Retirement Communities Association (ORCA). The convention will take place on Sunday, April 25th until Tuesday, April 27th at the Metro Toronto Convention Centre on the lower level.
The international First-line Radiosurgery for Small-Cell Lung Cancer (FIRE-SCLC) analysis led by University of Colorado Cancer Center researchers and published today in JAMA Oncology details clinical outcomes for 710 patients with brain metastases from small cell lung cancer treated with first-line stereotactic radiosurgery (SRS), without prior treatment with whole-brain radiation (WBRT) or prophylactic cranial irradiation (PCI).
NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, today announced that the Company will be presenting its Autologous Adult Stem Cell VSEL Technology for the Treatment of Battlefield Wounds at The USU-HJF Military Medicine Symposium in Washington DC, September 23rd, 2010.
› Verified 9 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 105 |
| Hospitalization Rate in facility | 156.5 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 258.9 |
| Hospitalization Rate: Lower Confidence Limit | 102.1 |
News Archive
Janssen Research & Development, LLC (Janssen) today announced it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for simeprevir, an NS3/4A protease inhibitor marketed as OLYSIO™ in the United States, in combination with the nucleotide analog NS5B polymerase inhibitor sofosbuvir developed by Gilead Sciences, Inc.
Guardian health editor Sarah Boseley examines why children have been excluded from WHO targets on non-communicable diseases (NCDs) in this post in her "Global Health Blog," writing, "Children die from cancer, heart disease and other NCDs but they are in danger of being forgotten as global targets for action are drawn up, say health groups."
The Ontario Long Term Care Association (OLTCA) is pleased to announce the opening of Together We Care Convention and Trade Show, jointly organized by OLTCA and the Ontario Retirement Communities Association (ORCA). The convention will take place on Sunday, April 25th until Tuesday, April 27th at the Metro Toronto Convention Centre on the lower level.
The international First-line Radiosurgery for Small-Cell Lung Cancer (FIRE-SCLC) analysis led by University of Colorado Cancer Center researchers and published today in JAMA Oncology details clinical outcomes for 710 patients with brain metastases from small cell lung cancer treated with first-line stereotactic radiosurgery (SRS), without prior treatment with whole-brain radiation (WBRT) or prophylactic cranial irradiation (PCI).
NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, today announced that the Company will be presenting its Autologous Adult Stem Cell VSEL Technology for the Treatment of Battlefield Wounds at The USU-HJF Military Medicine Symposium in Washington DC, September 23rd, 2010.
› Verified 9 days ago
The rate of readmission show you whether patients who were being treated regularly at RCG Orange Dc were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 29.3 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 41.7 |
| Readmission Rate: Lower Confidence Limit | 18.6 |
News Archive
Janssen Research & Development, LLC (Janssen) today announced it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for simeprevir, an NS3/4A protease inhibitor marketed as OLYSIO™ in the United States, in combination with the nucleotide analog NS5B polymerase inhibitor sofosbuvir developed by Gilead Sciences, Inc.
Guardian health editor Sarah Boseley examines why children have been excluded from WHO targets on non-communicable diseases (NCDs) in this post in her "Global Health Blog," writing, "Children die from cancer, heart disease and other NCDs but they are in danger of being forgotten as global targets for action are drawn up, say health groups."
The Ontario Long Term Care Association (OLTCA) is pleased to announce the opening of Together We Care Convention and Trade Show, jointly organized by OLTCA and the Ontario Retirement Communities Association (ORCA). The convention will take place on Sunday, April 25th until Tuesday, April 27th at the Metro Toronto Convention Centre on the lower level.
The international First-line Radiosurgery for Small-Cell Lung Cancer (FIRE-SCLC) analysis led by University of Colorado Cancer Center researchers and published today in JAMA Oncology details clinical outcomes for 710 patients with brain metastases from small cell lung cancer treated with first-line stereotactic radiosurgery (SRS), without prior treatment with whole-brain radiation (WBRT) or prophylactic cranial irradiation (PCI).
NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, today announced that the Company will be presenting its Autologous Adult Stem Cell VSEL Technology for the Treatment of Battlefield Wounds at The USU-HJF Military Medicine Symposium in Washington DC, September 23rd, 2010.
› Verified 9 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at RCG Orange Dc get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | .55 (As Expected) |
| SIR: Upper Confidence Limit | 1.33 |
| SIR: Lower Confidence Limit | .18 |
News Archive
Janssen Research & Development, LLC (Janssen) today announced it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for simeprevir, an NS3/4A protease inhibitor marketed as OLYSIO™ in the United States, in combination with the nucleotide analog NS5B polymerase inhibitor sofosbuvir developed by Gilead Sciences, Inc.
Guardian health editor Sarah Boseley examines why children have been excluded from WHO targets on non-communicable diseases (NCDs) in this post in her "Global Health Blog," writing, "Children die from cancer, heart disease and other NCDs but they are in danger of being forgotten as global targets for action are drawn up, say health groups."
The Ontario Long Term Care Association (OLTCA) is pleased to announce the opening of Together We Care Convention and Trade Show, jointly organized by OLTCA and the Ontario Retirement Communities Association (ORCA). The convention will take place on Sunday, April 25th until Tuesday, April 27th at the Metro Toronto Convention Centre on the lower level.
The international First-line Radiosurgery for Small-Cell Lung Cancer (FIRE-SCLC) analysis led by University of Colorado Cancer Center researchers and published today in JAMA Oncology details clinical outcomes for 710 patients with brain metastases from small cell lung cancer treated with first-line stereotactic radiosurgery (SRS), without prior treatment with whole-brain radiation (WBRT) or prophylactic cranial irradiation (PCI).
NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, today announced that the Company will be presenting its Autologous Adult Stem Cell VSEL Technology for the Treatment of Battlefield Wounds at The USU-HJF Military Medicine Symposium in Washington DC, September 23rd, 2010.
› Verified 9 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether RCG Orange Dc's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 88 |
| Transfusion Rate in facility | 24.8 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 60 |
| Transfusion Rate: Lower Confidence Limit | 11.4 |
News Archive
Janssen Research & Development, LLC (Janssen) today announced it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for simeprevir, an NS3/4A protease inhibitor marketed as OLYSIO™ in the United States, in combination with the nucleotide analog NS5B polymerase inhibitor sofosbuvir developed by Gilead Sciences, Inc.
Guardian health editor Sarah Boseley examines why children have been excluded from WHO targets on non-communicable diseases (NCDs) in this post in her "Global Health Blog," writing, "Children die from cancer, heart disease and other NCDs but they are in danger of being forgotten as global targets for action are drawn up, say health groups."
The Ontario Long Term Care Association (OLTCA) is pleased to announce the opening of Together We Care Convention and Trade Show, jointly organized by OLTCA and the Ontario Retirement Communities Association (ORCA). The convention will take place on Sunday, April 25th until Tuesday, April 27th at the Metro Toronto Convention Centre on the lower level.
The international First-line Radiosurgery for Small-Cell Lung Cancer (FIRE-SCLC) analysis led by University of Colorado Cancer Center researchers and published today in JAMA Oncology details clinical outcomes for 710 patients with brain metastases from small cell lung cancer treated with first-line stereotactic radiosurgery (SRS), without prior treatment with whole-brain radiation (WBRT) or prophylactic cranial irradiation (PCI).
NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, today announced that the Company will be presenting its Autologous Adult Stem Cell VSEL Technology for the Treatment of Battlefield Wounds at The USU-HJF Military Medicine Symposium in Washington DC, September 23rd, 2010.
› Verified 9 days ago
The rate of mortality show you whether patients who were being treated regularly at RCG Orange Dc lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 562 |
| Mortality Rate in facility | 12.9 (Better than Expected) |
| Mortality Rate: Upper Confidence Limit | 16.7 |
| Mortality Rate: Lower Confidence Limit | 9.8 |
News Archive
Janssen Research & Development, LLC (Janssen) today announced it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for simeprevir, an NS3/4A protease inhibitor marketed as OLYSIO™ in the United States, in combination with the nucleotide analog NS5B polymerase inhibitor sofosbuvir developed by Gilead Sciences, Inc.
Guardian health editor Sarah Boseley examines why children have been excluded from WHO targets on non-communicable diseases (NCDs) in this post in her "Global Health Blog," writing, "Children die from cancer, heart disease and other NCDs but they are in danger of being forgotten as global targets for action are drawn up, say health groups."
The Ontario Long Term Care Association (OLTCA) is pleased to announce the opening of Together We Care Convention and Trade Show, jointly organized by OLTCA and the Ontario Retirement Communities Association (ORCA). The convention will take place on Sunday, April 25th until Tuesday, April 27th at the Metro Toronto Convention Centre on the lower level.
The international First-line Radiosurgery for Small-Cell Lung Cancer (FIRE-SCLC) analysis led by University of Colorado Cancer Center researchers and published today in JAMA Oncology details clinical outcomes for 710 patients with brain metastases from small cell lung cancer treated with first-line stereotactic radiosurgery (SRS), without prior treatment with whole-brain radiation (WBRT) or prophylactic cranial irradiation (PCI).
NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, today announced that the Company will be presenting its Autologous Adult Stem Cell VSEL Technology for the Treatment of Battlefield Wounds at The USU-HJF Military Medicine Symposium in Washington DC, September 23rd, 2010.
› Verified 9 days ago
News Archive
Janssen Research & Development, LLC (Janssen) today announced it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for simeprevir, an NS3/4A protease inhibitor marketed as OLYSIO™ in the United States, in combination with the nucleotide analog NS5B polymerase inhibitor sofosbuvir developed by Gilead Sciences, Inc.
Guardian health editor Sarah Boseley examines why children have been excluded from WHO targets on non-communicable diseases (NCDs) in this post in her "Global Health Blog," writing, "Children die from cancer, heart disease and other NCDs but they are in danger of being forgotten as global targets for action are drawn up, say health groups."
The Ontario Long Term Care Association (OLTCA) is pleased to announce the opening of Together We Care Convention and Trade Show, jointly organized by OLTCA and the Ontario Retirement Communities Association (ORCA). The convention will take place on Sunday, April 25th until Tuesday, April 27th at the Metro Toronto Convention Centre on the lower level.
The international First-line Radiosurgery for Small-Cell Lung Cancer (FIRE-SCLC) analysis led by University of Colorado Cancer Center researchers and published today in JAMA Oncology details clinical outcomes for 710 patients with brain metastases from small cell lung cancer treated with first-line stereotactic radiosurgery (SRS), without prior treatment with whole-brain radiation (WBRT) or prophylactic cranial irradiation (PCI).
NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, today announced that the Company will be presenting its Autologous Adult Stem Cell VSEL Technology for the Treatment of Battlefield Wounds at The USU-HJF Military Medicine Symposium in Washington DC, September 23rd, 2010.
› Verified 9 days ago